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Although edible bird’s nest (EBN) has been shown to potentiate mitogenic responses, scientiﬁc evidence of its eﬃcacy is still
limited. In addition, human adipose-derived stem cells (hADSCs) are increasingly accepted as a source for stem cell therapy.
Therefore, the aim of this study was to investigate the eﬀects of the EBN extract (EBNE) on the proliferation of hADSCs
and its action mechanisms. We found that EBNE strongly promoted the proliferation of hADSCs. In addition, EBNE-induced
proliferation was found to be mediated through the production of IL-6 and VEGF, which was induced by activation of AP-1 and
NF-κB. Specially, we found that production of IL-6 and VEGF was induced by EBNE. In addition, EBNE-induced production of
IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-κB
inhibitor),butnotSP600125(aJNKinhibitor).Similarly,EBNE-inducedproliferationofhADSCswasalsoattenuatedbyPD98059,
SB203580, and PDTC but not SP600125. Taken together, these ﬁndings suggest that the EBNE-induced proliferation of hADSCs
primarily occurs through increased expression of IL-6 and VEGF genes, which is mediated by the activation of NF-κB and AP-1
through p44/42 MAPK and p38 MAPK.
1.Introduction
Edible bird’s nest (EBN) is the nest of the swift and is con-
structed with salivary glue, which is a cementing substance,
and may incorporate other materials such as vegetation or
feathers. Although EBN mainly contains carbohydrates,
amino acids, and mineral salts, its major ingredients are
glycoproteins [1]. Due to its nutritious and medical
properties, EBN has been deemed a precious food tonic in
Chinese community ever since the Tang (907AD) and
Sung (960–1279AD) dynasties [2]. Despite the long history
of using EBN for medicinal purpose, there have only been a
limited number of scientiﬁc reports on the health beneﬁts of
EBN. Recently, EBN has been found to potentiate mitogenic
response of human peripheral blood monocytes [3]a n d
stimulate DNA synthesis in 3T3 ﬁbroblasts [4].
G r o w t hf a c t o r ss u c ha se p i d e r m a lg r o w t hf a c t o r( E G F )
and vascular endothelial growth factor (VEGF) and cytok-
ines such as interleukin-6 (IL-6) play an important role in
cellular communication. As intercellular mediators, these
molecules regulate survival, growth, diﬀerentiation, and
eﬀector functions of cells [5–8]. In the case of stem cells, the
IL-6familyofcytokineshasbeenknowntobeinvolvedinthe
maintenance of both embryonic and adult stem cells [9, 10].
In addition, IL-6 was reported to increase the proliferation
of placenta-derived multipotent mesenchymal stem cells
(MSCs) [11]. Rehman et al. also demonstrated that human
adipose stromal cells secreted angiogenic and antiapoptotic
growth factors, such as VEGF, and hepatocyte growth factor
(HGF), in response to hypoxia and that conditioned media
containing these growth factors increased cell growth and
suppressed cell apoptosis [12].2 Evidence-Based Complementary and Alternative Medicine
Table 1: Amino acid distribution (mg/g) of edible bird’s nest
extract.
Name Total amino
acid (T)
Flee amino
acid (F)
(F/T) × 100
Aspartic acid 40.44 0.08 0.19
Threonine 22.39 1.32 5.89
Serine 29.47 0.84 2.85
Glutamic acid 51.78 0.27 0.52
Proline 21.07 0 0
Glycine 18.34 1.77 9.65
Alanine 18.44 2.79 15.13
Cysteine 41.06 0.06 0.14
Valine 24.35 8.88 36.46
Methionine 5.77 5.07 87.86
Isoleucine 16.65 8.36 50.21
Leucine 26.06 14.19 54.45
Tyrosine 17.16 11.83 68.93
Phenylalanine 29.37 16.19 55.12
Histidine 16.54 5.26 31.80
Lysine 15.23 6.08 39.92
Arginine 18.36 4.78 26.03
Tryptophan 06 . 0 2 100
MSCs are adult progenitor cells isolated primarily from
bone marrow or adipose tissue and can be rapidly expanded
in large numbers. MSCs are capable of diﬀerentiating into
several cell lineages, including osteoblasts, chondrocytes,
adipocytes, and myoblasts [13, 14]. In addition, MSCs were
reportedtobeinvolvedintherepairofinjuredtissuethrough
the secretion of cytokines, chemokines, and growth factors
[15–17]. Due to these properties, MSCs are becoming a
promising source of cells for various clinical applications
[18].
In the present study, we demonstrated that EBNE
promoted the proliferation of hADSCs and that its eﬀects
were mediated via the expression of IL-6 and VEGF through
the activation of NF-κB and AP-1, which were activated by
p44/42 MAPK and p38 MAPK.
2.MaterialandMethods
2.1. Preparation of Edible Bird’s Nest Extract (EBNE). EBN
was purchased from xiamen xiang long yan trade Co., Ltd
(Xiamen, China). The EBN was dried for 24h at 50◦Ca n d
then ground. The ground EBN was kept in distilled water at
50◦C for 30min. The suspension was treated with enzyme,
Protamex (ﬁnal concentration of 1% in water, Novozymes,
Bagsvaerd, Denmark) at 50◦Cf o r2 4 ha n dt h e nh e a t e da t
100◦C for 15 min to inactivate the enzyme. The supernatant
was obtained after centrifugation for 20min at 3,000×g
and subjected to ultraﬁltration using a 3,000Da cut-oﬀ
membrane.Theﬁltratedsamplecontainingcompoundswith
a molecular weight lower than 3,000Da was lyophilized
and then dissolved in Dulbecco’s modiﬁed Eagle’s medium
(DMEM,WelGENE,Daegu,Korea).Aminoaciddistribution
(mg/g) of EBNE was measured (Table 1).
2.2. Chemicals and Antibodies. MAPK inhibitors (PD98059,
SB203580, SP600125, PDTC), antibodies (p44/42,
phospho-p44/42 (Thr202/Tyr204), p38, phospho-p38
(Thr180/Tyr182) MAPK, stress-activated protein kinase/C-
Jun N-terminal kinse (SAPK/JNK), phospho-SAPK/JNK
(Thr183/Tyr185)), and phospho-IκB-α were all purchased
from Cell Signaling Technology, Inc (Beverly, Mass, USA).
2.3. Cell Culture. hADSCs were originally purchased from
Invitrogen (Carlsbad, Calif, USA) and cultured at 37◦C
u n d e r5 %C O 2 in MesenPRO RS medium (GIBCO, Carls-
bad, Calif, USA) with Growth supplement (GIBCO, Carls-
bad, Calif, USA). Normal human ﬁbroblasts (NHFs) were
obtained from Amorepaciﬁc, Inc. (Yongin, Korea) and
cultured in DMEM containing high-glucose levels, 10%
fetal bovine serum (FBS, GIBCO, Carlsbad, Calif, USA)
and 1% penicillin/streptomycin (Invitrogen, Carlsbad, Calif,
USA) at 37◦C under 5% CO2. Hep-3B (KCLB No. 88064)
and MCF-7 (KCLB No. 30022) were purchased from the
Korean Cell Line Bank (Seoul, Korea) and cultured in
DMEM containing high-glucose levels, 10% FBS and 1%
penicillin/streptomycin at 37◦C under 5% CO2.
2.4. Cell Proliferation. Cell proliferation was measured using
the MTT (3-[4,5-Dimethyl-2-thiazolyl]-2,5-diphenyl-2H-
tetrazolium bromide, USB Corp, Cleveland, Ohio, USA) and
assay. Cells (1 × 105) were plated in triplicate wells of 6 well-
plates and incubated overnight. The cells were then treated
with 2,000ppm EBNE for 60h under serum-free condition.
After treatment, MTT reagent (1mg/mL) was added to
each well. Cells were then incubated for 3h with MTT.
Medium was then removed and cells were solubilized with
dimethylsulphoxide (DMSO). Absorbance was measured at
a wavelength of 570nm using a spectrophotometer. As a
positive controls, cells were cultured in control medium
(DMEM + 15% FBS: hADSCs, Hep-3B, MCF-7 and NHFs;
DMEM + 10% FBS).
2.5. Cell Proliferation. Cell proliferation was measured using
theClick-iT EdUCytometry AssayKit(Invitrogen,Carlsbad,
Calif, USA) according to the manufacturer’s instructions.
1 × 105 cells were seeded in 60mm dishes and incubated
overnight. The cells were then treated with 2,000ppm EBNE
for 60h under serum-free conditions. The cells were then
labeled with EdU (10μM) for 3h, ﬁxed for 15min with
4% paraformaldehyde and permeabilized for 5min at room
temperature using Triton X-100 solution. The ﬁxed cells
were stained with the Click-iT reaction mixture for 30min
at room temperature, and then analyzed using a C6 Flow
Cytometer (Accuri Cytometers, Ann Arbor, Mich, USA).
2.6. Western Blotting. Western blotting was performed to
measure the levels of proteins associated with the MAPK
pathways. The protein extracts (40μg / l a n e )w e r el o a d e do n
a NuPAGE Novex 10% Bis-Tris Gel (Invitrogen, Carlsbad,
Calif, USA) and transferred to a nitrocellulose membrane.Evidence-Based Complementary and Alternative Medicine 3
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Figure 1: Eﬀe c t so fE B N Eo nt h ep r o l i f e r a t i o no fh A D S C s ,N H F s ,H e p - 3 B ,a n dM C F - 7 .( a ) – ( d )C e l l sw e r ec u l t u r e di ns e r u m - f r e eD M E M
in the presence or absence of the indicated concentrations of EBNE. Cell proliferation was then determined using the MTT assay. (a), (b),
(c), and (d) represent the proliferation of hADSCs, NHFs, Hep-3B, and MCF-7, respectively. For the positive control, cells were cultured
in control medium (DMEM+15% FBS: hADSCs, Hep-3B, MCF-7 and NHFs; DMEM+10% FBS). Values are represented as percentage
compared with the control. Results are shown as mean±SD (n = 3). ∗P<0.01 versus serum-free control. Data are representative of at
least three independent experiments. (e)–(h) Cell proliferation was determined using Click-iT EdU ﬂow cytometry. (e), (f), (g), and (h)
represent the proliferation of hADSCs, NHFs, Hep-3B, and MCF-7, respectively. Serum (−): serum-free, EBNE: 2,000ppm of EBNE. Data
are representative of at least three independent experiments.
The membranes were blocked with 5% bovine serum
albumin(BSA)for1handthenincubatedwithprimaryanti-
bodies, followed by incubation with horseradish peroxidase-
conjugatedanti-mouseorrabbitIgGsecondaryantibodyand
detected using PowerOpti-ECL Western blotting Detection
reagent (Anigen, Hwaseong, Korea).
2.7. ELISA. IL-6 and VEGF concentrations were quantiﬁed
in culture supernatants from hADSCs proliferation assays
using a commercially available ELISA kit (R&D systems,
Minneapolis, Minn, USA). Cell culture supernatants were
collected 60h after treatment with 2,000ppm EBNE and
assayed for IL-6 and VEGF. The standard curve was lin-
earized and subjected to regression analysis. The IL-6 and
VEGF concentration of the unknown samples was calculated
using the standard curve. All samples and standards were
measured in duplicate.
2.8. Cytokine Proﬁle. For quantitative analysis of cytokines,
supernatants of hADSCs cultured with 2,000ppm EBNE in
serum-freeDMEMfor60hwereanalyzedusingaﬂuorescent
beadimmunoassay,theFlowCytomixhumanbasickit(eBio-
science,SanDiego,Calif,USA),followingthemanufacturer’s
instructions. Brieﬂy, standards and cell supernatants were
placed in 96-well ﬁlter plates, and then coated beads and
biotinylated detection beads were added to all wells and
incubated for 2h. The mixture was then incubated with
PE-labelled streptavidin for 1h and measured using ﬂow
cytometry. Data were analyzed using the FlowCytomixPro
software (eBioscience, San Diego, Calif, USA).
2.9. RNA Extraction and Real-Time Quantitative Reverse
Transcription-PCR (RT-qPCR). Total RNA extraction
was carried out using the RNeasy kit (QIAGEN, Hilden,
Germany) for isolation of total RNA according to the4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Cytokine proﬁle analysis of hADSCs treated with EBNE. hADSCs were cultured in the presence of 2,000ppm EBNE for 60h.
EGF (column 1), FGF-2 (column 2), G-CSF (column 3), IL-6 (column 4), PDGF-BB (column 5), TGF-β1 (column 6), and VEGF (column
7). (a, b) hADSCs were cultured in serum-free DMEM in the presence or absence of 2,000ppm EBNE, and the concentration of produced
cytokines (pg/mL) was measured using a ﬂow cytometric bead assay. Results are shown as mean±SD in (a) (n = 2). ∗P<0.05 versus
serum-free controls. ∗∗∗NM indicates that treatment with EBNE-induced production of <30pg/mL of cytokines. Data are representative of
at least three independent experiments. (c, d) mRNA levels of IL-6 (c) and VEGF (d) were measured using real-time PCR. Results are shown
as mean±SD (n = 3). ∗P<0.05 versus serum-free controls. Serum (−): serum free, EBNE: 2,000ppm of EBNE.
manufacturer’s instructions. The ﬁrst cDNA was synthesized
usingaPrimeScript1ststrandcDNAsynthesiskit(TAKARA,
Tokyo, Japan) according to the manufacturer’s instructions.
To quantify cytokine gene expression, ﬂuorescence real-time
PCR was performed using the double-stranded DNA dye,
SYBR Green (Applied Biosystems, Foster city, Calif, USA).
Primer pairs for hIL-6 (sense, 5 -GGT ACA TCC TCG ACG
GCA TCT-3 ; antisense, 5 -GTG CCT CTT TGC TGC TTT
CAC-3 ), hVEGF (sense, 5 -CTA CCT CCA TGC CAA
GT-3 ; antisense, 5 - G C AG T AG C TG C GC T GA T AG A - 3  ),
and the control hGAPDH (sense, 5 -TGC ACC ACC AAC
TGC TTA GC-3 ; antisense, 5 -GGC ATG GAC TGT GGT
CAT GAG-3 ) were used to detect the target gene transcripts.
SYBR Green analysis was performed on an ABI PRISM
7300 system (Applied Biosystems, Foster city, Calif, USA)
according to the manufacturer’s instructions. All samples
were analyzed in triplicate, and the levels of the detected
mRNAs were normalized to control hGAPDH values. The
normalized data were used to quantify the relative levels of a
given mRNA according to the ΔCt analysis.
2.10. Transient Transfection and Luciferase Assay. hADSCs
were transfected with AP-1, CRE, and NF-κB-Luc reporter,
along with Renilla luciferase expression vector driven by
thymidine kinase promoter (Promega, Madison,W i s ,U S A )
using SuperFect transfection reagent (Qiagen, Valencia,
Calif,USA).Afterincubationfor24h,cellswereincubatedin
thepresenceor absenceofEBNE for24h.The cellswerethen
harvested and lysed. Supernatants were assayed for luciferase
activity. Luciferase activity was determined using a DualEvidence-Based Complementary and Alternative Medicine 5
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Figure 3: Eﬀects of EBNE on AP-1, NF-κB, or CRE promoter. hADSCs were transfected with AP-1 (a), NF-κB (b), or CRE (c) luciferase
reporters. After transfection, the cells were cultured with 2,000ppm EBNE for 24h, and then the luciferase assays were performed. Values
are expressed as relative fold increase in luciferase activity compared with the untreated controls. Results are shown as mean±SD (n = 3).
∗P<0.05 versus untreated controls. Data are representative of at least three independent experiments. Serum (−): serum-free, EBNE:
2,000ppm of EBNE.
Luciferase Assay system (Promega, Madison,W i s ,U S A )a n d
a LB953 luminometer (Berthold, Germany). The activity was
expressed as a ratio of the NF-κB-dependent ﬁreﬂy luciferase
activity to the control thymidine kinase Renilla luciferase
activity.
2.11. Immunophenotyping. 10 surface markers were ana-
lyzed by ﬂow cytometry. Markers of hMSCs (CD11b-PE,
CD14-APC, CD19-PE, CD34-PE, CD44-PE, CD45-APC,
CD73-APC, CD90-APC, CD105-PE, and HLA-DR-APC)
and negative control isotypes (PE-conjugated IgG1 k, and
APC-conjugated IgG1 k, PE-conjugated IgG2b k) were all
purchased from eBioscience, Inc. Cells (5×105) were seeded
in 100mm dishes and incubated overnight. The cells were
then treated with 2,000ppm EBNE for 60h under serum-
free conditions. After 60h, the cells were stained with the
indicated antibodies for 20min at room temperature and
then analyzed using ﬂow cytometry.
2.12. Statistical Analysis. All data were expressed as the
means±SD. Diﬀerences between the control and the treated
group were evaluated by a Student’s t-test using the Statview
software(AbacusConcepts,Cary,NC,USA).Forallanalyses,
a P<0.05 was considered statistically signiﬁcant.
3. Results
3.1. Eﬀects of EBNE on Cell Proliferation of hADSCs. We
ﬁrst examined the eﬀects of EBNE on cell proliferation
of hADSCs and NHFs under serum-free conditions. After
the cells were treated with various concentrations of EBNE
(500ppm, 1,000ppm, 2,000ppm, 4,000ppm, 8,000ppm),
cell proliferation was measured using the MTT assay. As
shown in Figures 1(a) and 1(b), EBNE concentration
dependently increased cell proliferation, which reached high
levels at 2,000ppm. Speciﬁcally, while EBNE induced a 34%
and 38% increase in the cell proliferation rate of hADSCs
and NHFs, respectively, compared to the untreated serum-
free group, no observable eﬀects on the two human cancer
cell lines tested (MCF-7, human breast cancer and Hep2B,
human liver cancer) were observed (Figures 1(c) and 1(d)).
These suggest that the EBNE eﬀects are limited to normal
cells and do not aﬀect transformed cell lines. The cell-
proliferating eﬀects of EBNE were further conﬁrmed using
the Click-iT EdU Flow cytometry assay. Similar to the
r e s u l t sp r e s e n t e di nF i g u r e s1(a)∼1(d), while the EBNE-
treated cells were shifted to the right when compared to the
untreated hADSCs and NHFs (Figures 1(e) and 1(f)), MCF-
7 and Hep2B cells were not aﬀected by EBNE (Figures 1(g)
and 1(h)). These results indicate that EBNE contributed to
the increased proliferation of hADSCs and NHFs, but not
human cancer cell lines.
3.2. Eﬀects of EBNE on Expression Proﬁle of Cytokine Genes.
MTT and ﬂow cytometry assays indicated that EBNE
was involved in the proliferation of hADSCs and HNFs.
Therefore, the eﬀects of EBNE on cytokine expression
in hADSCs were examined using a human ﬂuorescent
bead immunoassay in order to elucidate the mechanisms
behind EBNE-induced proliferation. Epidermal growth fac-
tor (EGF), ﬁbroblast growth factor-2 (FGF-2), granulocyte
colony-stimulating factor (G-CSF), interleukin-6 (IL-6),6 Evidence-Based Complementary and Alternative Medicine
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Figure 4: Eﬀects of EBNE on MAPKs. (a) hADSCs were starved for 24h and treated with 2,000ppm EBNE for the indicated times. Total cell
lysate was then prepared at 0, 5, 15, and 30min following EBNE stimulation and subjected to Western blot analysis. The bands for phospho-
p44/42, phospho-p38 MAPK, phospho-SAPK/JNK, and phosphor-IκB-α were detected and normalized to their total form and β-actin.
Results are shown as mean±SD. ∗P<0.05 versus untreated controls (0 time point). Data are representative of at least three independent
experiments. (b, c) hADSCs were starved for 24h and then treated with 50μM PD98059 or 5μM SB203580 or 20μMP D T Ci nt h ep r e s e n c e
of EBNE. The cell lysate was prepared at 5min (upon treatment of PD98059, PDTC) and 30min (upon treatment of SB203580) and then
subjectedtoWesternblotanalysis.Thebandsforphospho-p44/42,phospho-p38MAPK,andphosphor-IκB-αwere detected and normalized
to their total form and β- a c t i n .R e s u l t sa r es h o w na sm e a n± SD. #P<0.05 versus untreated controls. ∗∗P<0.05 versus EBNE (2,000ppm)
only. Data are representative of at least three independent experiments.
platelet-derived growth factor BB (PDGF-BB), transforming
growth factor-beta1 (TGF-β1), and vascular endothelial
growth factor (VEGF) were included in this study. The
levels of expression of IL-6 (166.5pg/mL±12.02) and VEGF
(227.5pg/mL±11.66) were signiﬁcantly high among these
cytokines (Figures 2(a) and 2(b)). However, no signiﬁcant
changes in the other cytokines were observed in response to
treatment with EBNE in hADSCs (Figures 2(a) and 2(b)). In
addition, EBNE-induced expression of IL-6 and VEGF was
alsofurtherconﬁrmedusingareal-timePCRassay.Asshown
in Figure 2(c), the mRNA levels of IL-6 and VEGF were
signiﬁcantly increased upon treatment with EBNE (Figures
2(c)and2(d)).TheseresultssuggestthatIL-6andVEGFplay
a critical role in the EBNE-induced proliferation of hADSCs.
3.3. AP-1 and NF-κB Signaling Are Involved in the EBNE-
InducedExpressionofIL-6andVEGFGenes. AP-1andNF-κB
regulate a variety of cellular genes that are important in the
maintenance of cellular physiology [19, 20]. To elucidate
which signaling pathways were involved in EBNE-induced
expressionofIL-6andVEGF genes,luciferasereporterassays
for AP-1, NF-κB and CRE were performed in hADSCs. In
this study, we found that EBNE induced activation of AP-1
and NF-κBp r o m o t e r s ,b u tn o tt h eC R Ep r o m o t e r( Figure 3),
suggesting that AP-1 and NF-κB signaling aﬀect EBNE-
induced expression of IL-6 and VEGF. To further investigate
the mechanisms behind these EBNE eﬀects, Western blot
analysis for the phosphorylated forms of p44/42 MAPK,
p38 MAPK, JNK, and IκB-α was performed. As shown in
Figure 4(a), while phosphorylation of p44/42 MAPK, p38
MAPK, and IκB-α was induced by EBNE, no signiﬁcant
changes in JNK phosphorylation were observed. In addi-
tion, EBNE-induced phosphorylation of p44/42 MAPK, p38
MAPK, and IκB-α was reduced by PD98059 (a p44/42
inhibitor), SB203580 (a p38 inhibitor), and PDTC (a NF-κB
inhibitor),respectively(Figures4(b)and4(c)).Furthermore,
IκB-α phosphorylation was reduced by PD98059, but were
not aﬀected by SB203580, suggesting that p44/42 MAPK also
contributes to NF-κBa c t i v a t i o n( Figure 4(c)).
3.4.EBNE-InducedProductionofIL-6andVEGFandProlifer-
ation of hADSCs Are Regulated by AP-1 Signaling and NF-κB
Signaling. To examine the involvement of AP-1 signaling
and NF-κB signaling in EBNE-induced production of IL-6
and VEGF and proliferation of hADSCs, ELISA for IL-6
and VEGF and the MTT assay were performed. As shown
in Figures 5(a) and 5(b), while EBNE-induced production
of IL-6 was reduced by PD98059 (a p44/42 inhibitor) and
PDTC (a NF-κB inhibitor), it was not reduced by SB203580
(a p38 inhibitor) and SB203580 only suppressed EBNE-
induced production of VEGF. These results indicate that
EBNE-induced expression of IL-6 is mediated through the
activation of p44/42 MAPK and NF-κB, and VEGF expres-
sion is only induced by p38 MAPK activation. In addition,
EBNE-induced proliferation of hADSCs was suppressed by
PD98059 (a p44/42 inhibitor), SB203580 (a p38 inhibitor),
a n dP D T C( aN F - κB inhibitor), respectively (Figure 5(c)).
Taken together, these results indicate that EBNE promotes
proliferation of hADSCs by inducing expression of IL-6 and
VEGF through the activation of NF-κB and AP-1.8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: Eﬀects of various inhibitors on the proliferation and cytokine expression in hADSCs. hADSCs were pretreated with the indicated
concentrations of MAPK inhibitors (PD98059, SB203580, SP600125) or NF-κB inhibitor (PDTC) for 3h and then further incubated in the
presenceof2,000ppmEBNE.IL-6andVEGFproductionwasanalyzedbyELISA(a,b).CellproliferationwasmeasuredusingtheMTTassay
(c). Results are shown as mean±SD (n = 3). ∗P<0.05 versus EBNE-treated controls. Data are representative of at least three independent
experiments.
3.5. Mesenchymal Stem Cell Properties of EBNE-Induced
hADSCs Are Maintained. Although EBNE was found to
promote the proliferation of hADSCs, eﬀects of EBNE on the
mesenchymal stem cell properties of hADSCs are unknown.
To examine this, FACS analysis was performed using sev-
eral mesenchymal stem cell (MSC) markers. As shown in
Figure 6,nosigniﬁcantchangesinMSCmarkersbetweenthe
serum-free group and EBNE-treated group were observed.
These results indicate that EBNE promotes proliferation
of hADSCs without impacting the mesenchymal stem cell
properties of hADSCs.
4. Discussion
In this study, we report novel ﬁndings in regards to the
proliferation of hADSCs induced by EBNE. We showed that
(1) EBNE induces expression of IL-6 and VEGF; (2) induced
expression of IL-6 and VEGF promotes proliferation of
hADSCs; (3) EBNE-induced expression of IL-6 is regulated
by activation of p44/42 MAPK and NF-κB; (4) VEGF
expression is induced by EBNE through the activation of p38
MAPK. Therefore, we demonstrated that EBNE promotes
the proliferation of hADSCs by upregulating expression ofEvidence-Based Complementary and Alternative Medicine 9
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Figure 6: FACS analysis of surface markers of hADSCs. Cells were cultured in serum-free DMEM in the presence or absence of EBNE.
The cells were then phenotyped using ﬂow cytometry. (c), (d), (g), and (h) represent the positive mesenchymal stem cell (MSC) markers
and (a), (b), (e), (f), (i), and (j) represent negative MSC markers. Red histograms show MSC speciﬁc markers, whereas isotype controls are
represented in the black histograms. Serum (−): serum free, EBNE: 2,000ppm of EBNE. Data are representative of at least two independent
experiments.
IL-6 and VEGF through the activation of NF-κB and AP-1
(p44/42 MAPK and p38 MAPK).
Stimulation with cytokines appears to play a crucial role
in important normal cellular processes [21]. IL-6 has been
shown to activate the JAK/STAT, MAPK, and AKT pathways
and has been implicated as potent mediators of numerous
important biological processes, including diﬀerentiation,
apoptosis and proliferation [7]. In addition, VEGF has been
showntopromotecellproliferationinresponsetohypoxiain
humanadiposestromalcells[12].Ithasalsobeenshownthat
VEGF production is mediated by a p38 MAPK-dependent
mechanism [22]. In this study, we found that IL-6 and VEGF
played an important role in the EBNE-induced proliferation
of hADSCs. Therefore, our current work, combined with
recent reports, supports a cell proliferation mechanism that
is dependent on the expression of IL-6 and VEGF.
The MAPK and NF-κB pathways, which involve a
series of protein kinase cascades, play a critical role in the
regulationofseveralchangesincellfunctionsuchascytokine
expression, proliferation, and apoptosis [23–26]. Therefore,10 Evidence-Based Complementary and Alternative Medicine
we hypothesized that the MAPK and NF-κBp a t h w a y sa r e
involved in the EBNE-induced expression of IL-6 and VEGF.
Inhibitors for MAPKs and NF-κBw e r eu s e dt oi n v e s t i g a t e
the involvement of MAPKs and NF-κB in the EBNE-induced
proliferation of hADSCs. In mammalian cells, three MAPK
cascades have been clearly characterized: p44/42 MAPK,
p38 MAPK, and C-Jun SAPK/JNK [27]. In addition, three
inhibitors for MAPKs were developed. PD98059 inhibits
MEKs, an upstream activator of p44/42, which blocks
p44/42-mediated signaling [28], SB203580 inhibits the p38
MAPK [29], and SP600125 inhibits SAPK/JNK [30]. In
our study, while expression of IL-6 gene was found to be
dependent on the activation of p44/42 MAPK and NF-κB,
p38 MAPK only played a central role in the expression of
VEGF. Consistent with this, EBNE-induced proliferation of
hADSCs was reduced by inhibitors for p44/42 MAPK, p38
MAPK, and NF-κB, demonstrating that MAPKs and NF-κB
promote proliferation of hADSCs through the upregulation
of IL-6 and VEGF.
A stem cell is deﬁned functionally as a cell with the
capacity for self-renewal, as well as the ability to generate
multiple diﬀerentiated cell types. Due to their capacity for
proliferation and specialization, combined with their active
self-renewalactivity,stemcellsarehighlyunique[14,31–34].
Thus, given their expected capacity for self-renewal, hADSCs
have been of great interest. The present study explored
the ability of EBNE to improve the self-renewal function
of hADSCs via an increase of the proliferative capacity.
We found that EBNE enhanced stem cell potency via an
increase in the proliferative capacity of hADSCs, suggesting
that EBNE can act as an extracellular factor that improves
self-renewal via an increase in the proliferative capacity of
hADSCs.Inaddition,althoughtheEBNEwasshowntoaﬀect
normal human cells, EBNE showed no signiﬁcant eﬀects on
the transformed cell lines (MCF-7 and Hep2B). These results
indicatethatEBNEcontributedtotheincreasedproliferation
of hADSCs and NHFs, but not human cancer cell lines,
suggestingthattheeﬀectsofEBNEarelimitedtonormalcells
and do not aﬀect transformed cell lines.
In this study, we evaluated the proliferation-inducing
eﬀectandthepossiblemechanismsbywhichEBNEimproves
the proliferation of hADSCs. Collectively, the results of this
study indicate that AP-1 (p44/42 MAPK and p38 MAPK)
and NF-κB-dependent production of IL-6 and VEGF plays
a crucial role in the EBNE-induced proliferation of hADSCs
under serum-free conditions.
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